Immunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy is vidofludimus calcium, an oral therapy being developed for relapsing and progressive MS. European Biotech spoke with Immunic’s CEO Erik Lundgren about the company’s clinical trials and commercial ambitions, the role of neuroprotection and why he believes the next major opportunity in MS may lie beyond relapse control.
Highlight Therapeutics’ skin cancer injections show promise in Phase 2b
Latest NewsSpain’s Highlight Therapeutics reported that its lead candidate, BO-112, met its Phase 2b endpoint in localized basal cell carcinoma, with 61% of evaluable patients achieving a response.
Europe’s CGT advantage at risk
slider, Sponsored PublicationsIndustry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global leadership.
Boehringer, Zealand obesity drug face tolerability questions after Phase 3 success
Latest NewsBoehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with overweight or obesity and type 2 diabetes, but gastrointestinal side effects caused 18% of patients receiving the drug to stop treatment.
Sanofi pays $1B upfront to expand Regeneron alliance beyond Dupixent
Latest NewsSanofi will pay Regeneron Pharmaceuticals $1 billion upfront (€0.9 billion) to expand the alliance that led to the blockbuster Dupixent with four antibody candidates designed to work longer between doses.
Atrogi’s muscle drug shows early power signal ahead of Phase 2
Latest NewsSwedish biotech Atrogi says its oral drug ATR-258 increased lower-extremity muscle power by about 13% after eight weeks in a study of 13 people with overweight or obesity. Participants also lost an average of 1.1 kg of fat mass and gained 0.8 kg of lean mass.
Immunic CEO: “We want to understand MS patients better than anyone”
Background, Latest NewsImmunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy is vidofludimus calcium, an oral therapy being developed for relapsing and progressive MS. European Biotech spoke with Immunic’s CEO Erik Lundgren about the company’s clinical trials and commercial ambitions, the role of neuroprotection and why he believes the next major opportunity in MS may lie beyond relapse control.
G 1/25: Form over function and how expensive is it?
slider, Sponsored PublicationsIn proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation of the description is an extensive and very costly writing exercise. There was inconsistent case law of the Boards of Appeal (TBoA) on whether and to what extent said adaptation is necessary. The Enlarged Board of Appeal (EBoA) has now decided, and it changes for the worse for the practitioner.
AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment
Latest NewsAstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates.
uniQure falls as Huntington’s gene therapy shows mixed results
Latest NewsuniQure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical significance on the main disease progression measure after four years. The Dutch biotech reported continued slowing of decline with AMT-130, but the update complicates the durability picture as the company seeks regulatory approval.
AnaCardio raises €62.5M to test heart failure drug
Latest NewsSwedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether early improvements in pumping function hold up in a larger patient population.